iShares Biotechnology ETF (NYSE Biotechnology) against SPDR S&P Biotech ETF (S&P Biotechnology Select Industry) — fees, long-horizon total returns, holdings overlap, and sector tilt, side by side.
| IBB | XBI | SPREAD | |
|---|---|---|---|
| YTD (cumulative) | — | +33.3% | — |
| 1Y CAGR | — | +80.7% | — |
| 3Y CAGR | — | +27.4% | — |
| 5Y CAGR | — | +4.36% | — |
| 10Y CAGR | — | +10.4% | — |
| Since inception CAGR | — | +12.1% | — |
Total return: dividend- and split-adjusted daily closes (distributions reinvested). Spread is IBB minus XBI. XBI since-inception measured from first available bar February 6, 2006. Since-inception spans differ — compare that row with care.
| IBB | XBI | |
|---|---|---|
| Name | iShares Biotechnology ETF | State Street SPDR S&P Biotech ETF |
| Category | Health | Health |
| Style | Passive | Passive |
| Expense ratio | 0.45% | 0.35% |
| Assets (AUM) | $9.2B | $9.6B |
| Dividend yield | 0.22% | 0.39% |
| Avg volume (3-mo) | 1.6M | 9.1M |
| Inception | February 5, 2001 | January 31, 2006 |
| Benchmark proxy | S&P 500 | S&P 500 |
XBI costs 0.1 pp less per year — about $10.00 per $10,000 invested.
| Shared holding | IBB | XBI | MIN |
|---|---|---|---|
| RVMDRevolution Medicines Inc Ordinary Shares | 2.85% | 1.32% | 1.32% |
Sum of min(weight in each fund) across shared tickers — the standard fund-overlap measure. Computed on the top 25 holdings each fund reports, so it is a lower bound; the coverage figures show how much of each fund those top holdings represent.
Expense ratios verified against issuer fact sheets. Dividend yield is trailing 12-month distributions divided by price, as reported by the fund data provider.